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Protocol
AbstrACt
Introduction Effective treatments are lacking for idiopathic 
intracranial hypertension (IIH), a condition characterised by 
raised intracranial pressure (ICP) and papilloedema, and 
found primarily in obese women. Weight loss and lowering 
body mass index (BMI) have been shown to lower ICP and 
improve symptoms in IIH; however, weight loss is typically 
not maintained, meaning IIH symptoms return. The Idiopathic 
Intracranial Hypertension Weight Trial (IIH:WT) will assess 
whether bariatric surgery is an effective long-term treatment 
for patients with IIH with a BMI over 35 kg/m2. The National 
Institute for Health and Care Excellence recommends bariatric 
surgery in people with a BMI over 35 kg/m2 and a qualifying 
comorbidity; currently IIH does not qualify as a comorbidity.
Methods and analysis IIH:WT is a multicentre, open-label, 
randomised controlled clinical trial of 64 participants with 
active IIH and a BMI over 35 kg/m2. Participants will be 
randomised in a 1:1 ratio to bariatric surgery or a dietary 
weight loss programme and followed up for 5 years. The 
primary outcome measure is ICP at 12 months. Secondary 
outcome measures include ICP at 24 and 60 months, and IIH 
symptoms, visual function, papilloedema, headache, quality of 
life and cost-effectiveness at 12, 24 and 60 months.
trial registration number IIH:WT is registered as 
ISRCTN40152829 and on  ClinicalTrials. gov as NCT02124486 
and is in the pre-results stage.
IntroduCtIon
Idiopathic intracranial hypertension
Idiopathic intracranial hypertension (IIH), 
also known as benign intracranial hyperten-
sion or pseudotumour cerebri, is a condi-
tion of unknown aetiology characterised by 
raised intracranial pressure (ICP) and papil-
loedema. IIH is found primarily in obese 
women (90%), causing daily headaches and 
visual loss, which can be severe and perma-
nent.1 2 Effective treatments are lacking and 
range from medical therapies to surgical 
procedures that offer symptomatic relief and 
prevent blindness.3 The overall age-adjusted 
and gender-adjusted annual incidence is 
reported as 1.8 per 100 000, with an increase 
from 1.0 per 100 000 (1990–2001) to 2.4 per 
100 000 (2002–2014; p=0.007)4; in line with 
the global obesity epidemic, the incidence 
of IIH is expected to rise.1 The increasing 
economic burden of IIH has been high-
lighted by a number of groups.5 6
Current therapy for IIH
The 2015 Cochrane review concluded there 
was insufficient evidence to determine which 
treatments are potentially beneficial in IIH3; 
hence, there is no clear guidance regarding 
standardised management.
strengths and limitations of this study
 ► This is the first randomised controlled trial to 
evaluate the efficacy of long-term weight loss 
strategies to modify underlying disease in idiopathic 
intracranial hypertension (IIH).
 ► This trial will drive changes in clinical practice and 
impact on IIH treatment guidance.
 ► Cost-effectiveness will be assessed with relevance 
to future policy decisions.
 ► A potential limitation could be that there were limited 
data available to inform the sample size calculation, 
as so few trials have been performed in this area.
 ► The body mass index (BMI) eligibility in this trial is 
in line with current UK National Institute for Health 
and Care Excellence guidelines for bariatric surgery; 
however, the benefits of weight loss may be relevant 
to those with a lower BMI.
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Medical therapy can be used with the aim of lowering 
ICP. The Idiopathic Intracranial Hypertension Treatment 
Trial demonstrated acetazolamide has beneficial effects 
in patients with mild visual loss.7 However, a pilot trial in 
the UK suggested many patients do not tolerate the drug 
well.8 Topiramate has also been evaluated in IIH, but in 
the absence of a placebo arm it is difficult to interpret the 
results of this study.9
In cases of deteriorating vision, surgical techniques 
such as cerebrospinal fluid (CSF) diversion (shunting), 
optic nerve sheath fenestration (ONSF) or venous sinus 
stenting can be used to prevent blindness.10 Shunting 
is generally not a satisfactory treatment, with a high 
revision rate.11 There is significant morbidity from CSF 
shunting.11 12 The evidence for ONSF is mainly case-
based,13 with reports of ongoing visual decline in a 
third of patients at 1 year and in nearly half at 3 years.14 
The evidence for venous sinus stenting is based on case 
series and retrospective studies, and long-term data are 
limited.1 2 Patients waiting for surgical intervention and 
suffering disabling headaches with very high pressures 
may be offered repeated lumbar punctures (LP) to lower 
ICP, offering symptomatic relief.
Weight loss
We published a prospective study showing that a very 
low calorie diet leading to significant weight loss 
(15.3%±7.0% of body weight) significantly lowered ICP 
(8.0±4.2 cmCSF, p<0.001) and significantly improved 
papilloedema, vision and headache.15 However, patients 
in our study later regained weight and their symptoms 
and signs of IIH returned, a documented phenomenon 
in the condition.16
Despite the recurrence of IIH following weight regain, 
our study demonstrates the efficacy of therapeutic weight 
loss. However, maintaining long-term weight loss is 
difficult to achieve, with patients on average regaining 
one-third to one-half of lost weight at 12 months, and 
returning to original weight in 5 years.17 18 Sustainable 
approaches to weight loss are therefore likely to offer 
patients an effective treatment. Obesity pharmacological 
therapies such as orlistat are unlikely to achieve sufficient 
weight loss (typical reduction of 2.89 kg)19 to significantly 
modify IIH.
bariatric surgery for IIH
Bariatric surgery has many advantages as a potential treat-
ment for IIH:
1. Weight loss is greater than other weight-reducing 
approaches.20 Hutter et al21 give a mean reduction 
in body mass index (BMI) of 7.05–15.34 m/kg2 at 12 
months using the three procedures in use in this trial.
2. Weight loss is sustained.22–25 Although the most re-
cent Cochrane review notes that follow-up in bariat-
ric surgery trials is often only 12–24 months and so 
long-term effects are unclear,20 one prospective obser-
vational study showed a mean weight loss of 17% at 10 
years.25 Weight loss peaks at 12–24 months.24 25
3. Bariatric surgery is cost-effective compared with 
non-surgical interventions to manage obesity.26
4. Bariatric surgery is safe. Mortality rates are typically 
0.05%–0.14%, similar to cholecystectomy or 
hysterectomy.21 27 28 Depending on patient complexity, 
this can rise as high as 2%,29 but our patient population 
is typically younger and healthier than the average 
bariatric surgery patient. Major complications rates 
are 2%–6%,21 27–33 similar to other common elective 
operations.27
The National Institute for Health and Care Excellence 
recommends bariatric surgery for people with a BMI over 
40 kg/m2 or in people with a BMI of over 35 kg/m2 and a 
significant comorbidity (e.g. type 2 diabetes) that may be 
improved with weight loss.34 IIH is not one of the listed 
comorbidities, and patients with IIH do not often have 
alternative comorbidities that would qualify them for 
surgery.
There are no published systematic reviews or meta-anal-
yses of weight modification or bariatric surgery in IIH, 
although an increasing number of case series and reports 
have been published describing its beneficial effects.35 
There are no long-term data about sustained weight loss 
in IIH.
rationale
The aim of this trial is to assess if sustained weight loss 
results in sustained reduction of ICP, visual symptoms 
and headaches, and which method, bariatric surgery or 
a dietary weight loss programme, is a viable method to 
achieving this.
Bariatric surgery is an approach to sustainable signifi-
cant weight loss, and so may offer long-term treatment of 
IIH. Participants will receive a range of bariatric surgeries 
that will broadly reflect current practice in the National 
Health Service (NHS) and will be chosen by participant 
and surgeon to best suit their preferences and any comor-
bidities. This range of procedures has been chosen so that 
results will be as generalisable as possible to patients in 
the NHS rather than dependent on one procedure type. 
Different procedures result in different mean weight 
loss, but all three procedures in use in this trial should 
result in sufficient weight loss to be disease-modifying 
according to our weight loss study.15 Different metabolic 
effects from different procedures may additionally result 
in disease modification; this will be detected through the 
analysis of biomarkers from both blood and CSF samples, 
and we will check for heterogeneity in outcomes between 
the three bariatric procedures included in the trial.
Bariatric surgery is an invasive approach to weight 
reduction and a significant change from the current 
accepted treatment for IIH. As it is not established how 
much weight loss is necessary to treat IIH, conservative 
weight management with dietary interventions may also 
offer long-term treatment. To impact current clinical 
practice, we will compare bariatric surgery with an alter-
native weight loss regimen (rather than current prac-
tice). The comparator arm will be a dietary weight loss 
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programme using the internationally recognised Weight 
Watchers diet programme.
Weight Watchers is a widely available commercial 
weight loss programme achieving superior weight 
loss and attendance compared with other commer-
cially available (such as Slimming World or Rosemary 
Conley) or primary care-led weight loss programmes.36 
Participants in Weight Watchers receive group support, 
access to online tools, and resources and advice on 
healthy eating. In one study, participants in Weight 
Watchers lost on average 4.4 kg 3 months after joining 
the programme.36
Participants in the Idiopathic Intracranial Hyperten-
sion Weight Trial (IIH:WT) will be randomised between 
referral to bariatric surgery or to a dietary weight loss 
programme (Weight Watchers) for 12 months.
MetHods
design
IIH:WT is a multicentre, randomised controlled, paral-
lel-arm, clinical trial of 64 participants with active IIH and 
a BMI over 35 kg/m2. Participants will be randomised in a 
1:1 ratio to either bariatric surgery or a dietary weight loss 
programme and followed up for 5 years.
blinding
The trial will necessarily be open-label due to the nature 
of the intervention; assessors of visual outcomes will be 
masked to randomised treatment allocation. The primary 
outcome, ICP, is an objective measure.
recruitment
Patients will be identified at neurology and ophthal-
mology clinics in UK NHS Trusts between March 2014 
and October 2017.
The participant pathway through the trial is shown in 
figure 1.
Inclusion criteria and exclusion criteria
The following are the inclusion criteria:
1. female patients with IIH aged between 18 and 55 
years, diagnosed according to the Friedman Jacobson 
criteria,37 who have active disease (papilloedema 
(Frisén grade ≥1 in at least one eye), significantly 
raised ICP >25 cmCSF) of over 2 months’ duration 
and no evidence of venous sinus thrombosis (MRI or 
CT and venography as noted at diagnosis)38
2. BMI >35 kg/m2
3. tried other appropriate non-surgical treatments to 
lose weight but have not been able to achieve or main-
tain adequate, clinically beneficial weight loss for at 
least 6 months
4. able to give informed consent.
The following are the exclusion criteria:
1. age less than 18 or older than 55 years
2. pregnant
3. significant comorbidity, Cushing’s syndrome, Ad-
dison’s disease or the use of oral or injected steroid 
therapy
4. undergone ONSF
5. definite indication for or contraindication against sur-
gery or dieting
6. have a specific medical or psychiatric contraindication 
for surgery, including drug misuse, eating disorder or 
major depression (suicidal ideation, drug overdose or 
psychological admission in the last 12 months)
7. previous bariatric surgery
8. inability to give informed consent, for example, due 
to cognitive impairment.
Apart from the trial treatments allocated at randomi-
sation, other aspects of patient management (e.g. use of 
acetazolamide or topiramate) are at the discretion of the 
local doctors.
randomisation
Participants are randomised into the trial by telephone call 
to the Birmingham Clinical Trials Unit. A computer-gen-
erated randomisation list with allocation of treatment 
stratified by acetazolamide use will be used. Stratification 
will not be according to topiramate as well as acetazol-
amide use due to the low number of participants.
treatment arms
Intervention arm
 ► Participants randomised to surgery will be referred to 
bariatric surgery. If judged suitable according to the 
local screening processes, the participant will undergo 
laparoscopic adjustable gastric banding, Roux-en-Y 
gastric bypass or laparoscopic sleeve gastrectomy. This 
will take approximately 4 months from randomisa-
tion to surgery. The choice of surgery will be made 
between the surgeon and the participant based on 
the participant’s health and preference, and standard 
NHS follow-up will be included.
Active control arm
 ► Participants randomised to the dietary weight loss 
programme will be given vouchers allowing access to 
weekly meetings at their local Weight Watchers group 
and Weight Watchers online and mobile tools for 12 
months.
Follow-up and outcome measures
Primary outcome measure
 ► ICP at 12 months.
Secondary outcome measures
 ► ICP at 24 and 60 months
 ► reported IIH symptoms (pulsatile tinnitus, visual loss, 
diplopia, visual obscurations)
 ► visual function (logMAR chart to assess visual acuity, 
Humphrey visual fields (HVF) 24–2, Mars charts to 
assess contrast sensitivity, Ishihara colour vision)
 ► papilloedema (measured by spectral optical coher-
ence tomography and fundus photography)
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 ► headache-associated disability (headache diary, Head-
ache Impact Test-6 score (HIT-6))
 ► anthropometric measures (BMI, waist/hip ratio, fat 
mass, blood pressure)
 ► quality of life and well-being (EuroQol 5 Dimen-
sions (EQ-5D-5L) questionnaire, ICEpop CAPability 
measure for Adults (ICECAP-A), RAND 36-Item Short 
Form Survey (SF-36), Hospital Anxiety and Depres-
sion score)
 ► difference in number of referrals to CSF shunting and 
ONSF procedures between treatment arms
 ► change in quality-adjusted life years and/or capability 
well-being; offset against cost of treatment.
All outcomes will be measured at 12, 24 and 60 months.
exploratory objectives
Participants with IIH and 20 matched obese control 
participants will give samples of blood (36 mL) and 
CSF (10 mL) at baseline and 12, 24 and 60 months for 
fasting metabolic evaluation, evaluation of polycystic 
ovary syndrome status, and exploratory analysis including 
biomarkers such as fasting insulin.
Some participants, including the 20 matched obese 
controls, will participate in substudies looking at the aeti-
ology of IIH and the relationship between IIH and other 
obesity comorbidities, from which they may suffer. The 
substudies include a sleep apnoea observational substudy, 
a cognitive function substudy, an MRI substudy and a meta-
bolic syndrome substudy. Patients will be assessed at baseline 
(to evaluate the presence of comorbidities in our patient 
population and for comparison to the matched obese 
control patients) and at 12 months (to evaluate possible 
changes due to weight loss). These substudies will not be 
carried out at all sites and are not discussed in further detail 
in this paper. The control participants will undergo the 
Figure 1 Participant pathway from approach to primary endpoint. ICP, intracranial pressure; LP, lumbar puncture.
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same baseline assessment as randomised participants and 
then exit the study.
Format of assessment visits
When initially approached, participants will be asked to 
consent to a prescreening assessment. This will consist of 
having their papilloedema assessed and graded according 
to the modified Frisén criteria. If papilloedema is present 
the participant will be asked to return for a screening 
visit. In the 7 days before the screening visit, the partic-
ipant will complete a headache diary recording severity 
and frequency of headache, as well as analgesic use.
Participants will then have a screening assessment (0 
months), which will be carried out according to figure 2 
and is described below.
Informed consent will first be taken and a urine preg-
nancy test carried out. Then the participant will undergo 
a series of visual assessments. If any of these assessments 
have been carried out in the 30 days prior to the screening 
visit as part of routine care, then they will not be repeated, 
but the results taken from patient notes provided they 
have been performed as per trial protocol.
The visual assessments will be recorded in both eyes 
and these include the following:
 ► Best corrected visual acuity will be measured using 
logMAR (log of the minimum angle of resolution) 
charts.
 ► Best corrected contrast sensitivity will be measured 
using Mars charts.
 ► Colour vision will be assessed using the Ishihara pseu-
do-isochromatic plates.
 ► Automated perimetry with an HVF analyser using 
the SITA (Swedish Interactive Thresholding Algo-
rithm) Standard 24–2 program. Where there is a high 
false-positive rate, the HVF will be repeated prior to 
LP.
 ► Optical coherence tomography (Heidelberg Spec-
tralis spectral domain optical coherence tomography 
(OCT)) will be acquired to record measurements 
including retinal nerve fibre layer. OCT scans will 
be sent for masked review by designated specialist 
readers.
 ► Digital colour fundus photographs will be taken, 
centred on the optic disc with focus on the anterior 
surface of the swollen nerve head. These will be 
graded by masked reviewers.
After visual assessments are complete, an LP will be 
performed. LP will be performed with the participant 
breathing steadily in the lateral position, legs flexed 90o 
at the hip, with adequate time taken to ensure a stable 
reading. ICP will be recorded in cmCSF. Where required, 
LP will be performed with image guidance.
The LP will be carried out after all visual assessments 
as the LP temporarily lowers ICP and so potentially alters 
visual measurements. In all cases the LP will be done on 
the day of randomisation as ICP is the primary outcome.
Further assessment of headache will use the HIT-6,39 an 
assessment of the impact of headache over the previous 
month. Headache preventative use (eg, topiramate) and 
use of acetazolamide/diuretics will be recorded.
The participant will complete quality of life question-
naires (QoL) following the LP. These include the generic 
health-related QoL questionnaires EQ-5D-5L, SF-36 
Version 1 and ICECAP-A, and the Hospital Anxiety and 
Depression score.
If participants have ICP >25 cmCSF, they will be 
randomised, and the data collected at the prescreening 
and screening visits will be used for baseline data.
Participants will then be evaluated at 3, 6, 12, 24 and 
60 months as shown in table 1. Participants randomised 
to surgery will also be evaluated at approximately 2 weeks 
postsurgery for an LP assessment of ICP.
Analysis
Sample size
The sample size is 64 with 32 participants in each arm 
(bariatric surgery vs dietary weight loss programme).
For this trial we hypothesise that the greater weight loss 
anticipated in the bariatric surgery arm compared with the 
dietary arm will consequently reduce the ICP further in 
the bariatric arm than in the dietary arm. A weight loss of 
15.3%±7.0% of body weight over 3 months was achieved by 
patients following a low-calorie diet.15 Data from this study 
showed that ICP was significantly reduced by 20% (ICP at 
baseline in 20 patients with IIH was 39.8±5.1 cmCSF and ICP 
was reduced by 8±4.2 cmCSF, p<0.001).
Assuming a conservative change of ICP in the bariatric 
surgery arm to that previously observed of 8 cmCSF and a 
change of 3 cmCSF in the dietary arm (to reflect changes 
Figure 2 The format of the baseline visit is shown. HVF, 
Humphrey visual field; ICP, intracranial pressure; OCT, optical 
coherence tomography.
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slightly greater than the baseline fluctuations seen in our 
previous study), we wish to detect a mean difference of 5 
cmCSF between the groups. To detect this difference of 5 
cmCSF with 90% power and alpha=0.05 using a two-sided 
t-test (assuming an SD of 5.1)15 requires 46 patients (23 
per arm). Allowing for a 28% dropout rate will require 32 
patients per arm.
We believe that the SD of 5.1 is a true reflection of the 
variability of the data as this is taken from the baseline 
measurements from our previous study, in a similar popu-
lation.15 This assumption for the sample size calculation 
will be monitored during the trial.
Projected accrual and attrition rates
Recruitment for our previous study with very similar inclu-
sion criteria was at a rate of 1.5 participants per month15; 
we consequently feel that the recruitment target of 1.4 
participants per month (64 participants over 45 months) 
is realistic and achievable. Attrition rates for this treatment 
and patient group are not known; we have allowed a 28% 
rate of dropout. Attrition will be monitored by the Trial 
Management Group and by the oversight committees, 
and we will attempt to improve participant engagement 
through participant newsletters, participant compensa-
tion, patient support days and engagement with the IIH 
UK patient charity.
statistical analysis
The primary comparison groups will be composed of 
those randomised to the bariatric surgery arm and those 
randomised to the dietary weight loss arm. Analyses will 
be based on the intention-to-treat principle, that is, all 
patients will be analysed in the treatment group to which 
they were randomised irrespective of compliance with the 
randomised allocated treatment or other protocol viola-
tions. Summary statistics and differences between groups 
(eg, mean differences, relative risks) will be reported, 
with 95% CIs and p values from two-sided tests given. 
Outcomes will be adjusted for the stratification variable 
(acetazolamide use at entry). For all analyses, a p value 
<0.05 will be considered statistically significant, and there 
will be no adjustment for multiple testing.
Primary outcome analysis
The primary outcome will assess the ICP at 12 months. 
The ICP at 12 months for the two study arms will be 
Table 1 Outcome measures and assessments
Outcome Measure Baseline 3 months 6 months Postoperative
 12 months 
(primary 
endpoint) 24 months 60 months
ICP Lumbar puncture x x x x x
Clinical 
measures
BMI, 
blood pressure, 
waist/hip, fat mass, 
medication use
x x x x x x x
IIH symptoms Pulsatile tinnitus, 
visual loss, 
diplopia, visual 
obscurations
x x x x
Visual 
function
Visual acuity, 
contrast sensitivity, 
colour assessment
x x x x
Humphrey visual 
field (24–2)
x x x x
Papilloedema Optical coherence 
tomography
x x x x
Retinal 
photographs
x x x x
Headache HIT-6, headache 
diary
x x x x
Quality of life EQ-5D-5L, 
ICECAP-A, SF-36 
v1, HADS
x x x x
Health 
economics
Resource use 
questionnaire
x x x x
BMI, body mass index; EQ-5D-5L, EuroQol 5 Dimensions questionnaire; HADS, Hospital Anxiety and Depression Scale; HIT-6, Headache 
Impact Test-6; ICECAP-A, ICEpop CAPability measure for Adults; ICP, intracranial pressure; IIH, idiopathic intracranial hypertension; SF-36 
v1, RAND 36-Item Short Form Survey Version 1.
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compared using a linear regression model with baseline 
ICP and acetazolamide use at entry (stratification vari-
able) included as covariates in the model.
Secondary outcome analyses
Secondary outcome measures include a mixture of contin-
uous and categorical data items. Continuous outcomes 
(eg, quality of life) will be analysed as per the primary 
outcome measure. Categorical outcomes (eg, presence 
or absence of symptoms, number of CSF shunting refer-
rals) will be expressed as the number and percentage of 
patients experiencing these outcomes in the two groups. 
Log-binomial models will be used to compare the data 
between the two study arms, with baseline data (where 
available, i.e. baseline symptom data) and acetazolamide 
use at entry (stratification variable) included in the model 
as covariates.
Health economic outcomes
The following analyses will assess the cost-effectiveness of 
bariatric surgery versus diet for IIH:
1. Cost-effectiveness analysis—ICP measured at baseline 
and 12 months will be evaluated in terms of cost to 
reduce ICP by 12.5%.
2. Cost-utility analysis—quality of life and well-being in-
formation from the EQ-5D-5L and ICECAP-A ques-
tionnaires at baseline and 12 months; cost-effective-
ness will be expressed as ‘cost per QALY gained’ and 
‘cost per sufficient and full capability achieved’.
3. Cost-benefit analysis—monetary outcomes will 
be elicited using the ‘Willingness to Pay’ method 
asked at baseline and at 12 months. Results will be 
expressed as a cost:benefit ratio and net-present 
value.
Monitoring
Safety reporting
There are no novel medical devices or investigational 
medicinal products used as part of this trial. Any serious 
adverse events (SAEs) including surgical mortality and 
complications will be reported on a trial-specific SAE 
form, evaluated by the Chief Investigator, and where 
required reported to sponsor and ethics committee.
Independent Trial Steering Committee
A Trial Steering Committee will provide oversight of the 
study. The independent members are a consultant neurol-
ogist and neuro-ophthalmologist as chair, a consultant 
bariatric surgeon as independent expert, an independent 
statistician, and a patient representative.
Data Monitoring Committee
A Data Monitoring Committee will independently 
monitor the efficacy and safety data at least annually. The 
members are a consultant ophthalmologist as chair, a 
consultant bariatric surgeon as independent expert and 
an independent statistician.
Compliance monitoring
Data on compliance in the bariatric surgery arm will be 
collected from local surgery teams. Compliance will be 
considered as undergoing bariatric surgery. Reasons for 
non-compliance will be recorded.
Data on attendance to Weight Watchers for participants 
in the dietary arm will be self-reported and given in terms 
of percentage of sessions attended. It is not expected that 
participants will attend every session (30% of participants 
attended less than 50% of sessions over 12 weeks in one 
trial36 and we expect a lower attendance rate over 12 
months).
ethics and dissemination
The National Research Ethics Committee West Midlands 
– The Black Country approved IIH:WT on 28 February 
2014 (14/WM/0011).
The trial will be conducted according to the standards 
of the International Conference on Harmonisation-Good 
Clinical Practice and the Research Governance Frame-
work for Health and Social Care. Written informed 
consent will be provided by all patients prior to any 
trial-related procedures. Participants will be free to with-
draw from the trial at any time without any effect on their 
standard of care.
Results will be disseminated through internal reports, 
relevant conferences, peer-reviewed scientific journals 
and online publications.
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